董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Willard H. Dere | 男 | Director | 72 | 12.45万美元 | 未持股 | 2026-03-12 |
| Eric D. Shaff | 男 | Director | 50 | 313.59万美元 | 未持股 | 2026-03-12 |
| Richard N. Kender | 男 | Director and Executive Chair and Interim Chief Executive Officer | 70 | 13.64万美元 | 未持股 | 2026-03-12 |
| Kurt C. Graves | 男 | Director | 58 | 12.64万美元 | 未持股 | 2026-03-12 |
| Stephen Berenson | 男 | Director | 65 | 14.42万美元 | 未持股 | 2026-03-12 |
| Robert Rosiello | 男 | Director | 68 | 未披露 | 未持股 | 2026-03-12 |
| Hans Juergen Woerle | 男 | Director | 60 | 未披露 | 未持股 | 2026-03-12 |
| Claire M. Fraser | 女 | Director | 71 | 未披露 | 未持股 | 2026-03-12 |
| Dennis A. Ausiello | 男 | Director | 80 | 11.82万美元 | 未持股 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard N. Kender | 男 | Director and Executive Chair and Interim Chief Executive Officer | 70 | 13.64万美元 | 未持股 | 2026-03-12 |
| Marella Thorell | 女 | Chief Financial Officer and Executive Vice President | 59 | 未披露 | 未持股 | 2026-03-12 |
| Matthew Henn | 男 | Chief Scientific Officer and President | 51 | 85.95万美元 | 未持股 | 2026-03-12 |
| Teresa L. Young | 女 | Chief Commercial and Strategy Officer and Executive Vice President | 59 | 未披露 | 未持股 | 2026-03-12 |
| Marella Thorell | 女 | Chief Financial Officer and Executive Vice President | 58 | 未披露 | 未持股 | 2026-03-12 |
| Kelly Brady | 女 | Chief Operating Officer and Executive Vice President | 42 | 未披露 | 未持股 | 2026-03-12 |
| Thomas J. DesRosier | 男 | Chief Legal Officer and Executive Vice President | 71 | 143.73万美元 | 未持股 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- Willard H. Dere
-
Willard H. Dere，他一直担任董事会成员（2017年7月以来）。Dere博士自2014年11月起担任内科教授，B. Lue和Hope S. Bettilyon糖尿病研究内科教授，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心联合首席研究员，自2019年9月起担任研究助理副总裁。在担任教授之前，从2003年到2014年10月退休，他在Amgen， Inc.担任多个职位，包括全球发展主管，公司和国际首席医疗官，并领导各种治疗领域的项目开发。Dere博士担任多家公司的董事会成员，包括BioMarin Pharmaceutical， Inc.（2016年以来）和Radius Health（2014年以来）。从2016年10月到2017年12月，他担任Ocera Therapeutics的董事会成员。他在California大学Davis分校获得历史学、动物学和医学博士学位，在Utah大学完成了内科住院医师培训，并在加州大学旧金山分校完成了内分泌学和新陈代谢博士后培训。
Willard H. Dere has served as a member of board of directors since July 2017. Dr. Dere has served as Chief Advisor to the Chief Executive Officer and Chief Medical Officer of Angita Bio, a biotechnology company, since July 2022. Dr. Dere has also been Professor Emerit, Department of Internal Medicine, at the University of Utah School of Medicine since July 2022. From November 2014 until June 2022, Dr. Dere held multiple roles at the University of Utah Health Sciences Center, including Associate Vice President for Research, Co Director of the Utah Clinical and Translational Science Institute, and Co Director of the Center for Genomic Medicine. Prior to his professorship, from 2003 until 2014, Dr. Dere worked at Amgen, where he was Senior Vice President and head of Global Development, and led development programs in multiple therapeutic areas. From 1989 to 2014, he worked at Eli Lilly and led multiple development programs, and also worked in clinical pharmacology, regulatory affairs and safety. Dr. Dere has served on the boards of directors of BioMarin Pharmaceutical, Inc. since 2016 and Metagenomi, Inc. since Augt 2021, and previoly served on the boards of directors of Mersana Therapeutics, Ocera Therapeutics and Radi Health. Dr. Dere received his B.A. in History and Zoology and M.D. from the University of California, Davis, completed his internal medicine residency training at the University of Utah, and his postdoctoral training in endocrinology and metabolism at the University of California, San Francisco. - Willard H. Dere，他一直担任董事会成员（2017年7月以来）。Dere博士自2014年11月起担任内科教授，B. Lue和Hope S. Bettilyon糖尿病研究内科教授，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心联合首席研究员，自2019年9月起担任研究助理副总裁。在担任教授之前，从2003年到2014年10月退休，他在Amgen， Inc.担任多个职位，包括全球发展主管，公司和国际首席医疗官，并领导各种治疗领域的项目开发。Dere博士担任多家公司的董事会成员，包括BioMarin Pharmaceutical， Inc.（2016年以来）和Radius Health（2014年以来）。从2016年10月到2017年12月，他担任Ocera Therapeutics的董事会成员。他在California大学Davis分校获得历史学、动物学和医学博士学位，在Utah大学完成了内科住院医师培训，并在加州大学旧金山分校完成了内分泌学和新陈代谢博士后培训。
- Willard H. Dere has served as a member of board of directors since July 2017. Dr. Dere has served as Chief Advisor to the Chief Executive Officer and Chief Medical Officer of Angita Bio, a biotechnology company, since July 2022. Dr. Dere has also been Professor Emerit, Department of Internal Medicine, at the University of Utah School of Medicine since July 2022. From November 2014 until June 2022, Dr. Dere held multiple roles at the University of Utah Health Sciences Center, including Associate Vice President for Research, Co Director of the Utah Clinical and Translational Science Institute, and Co Director of the Center for Genomic Medicine. Prior to his professorship, from 2003 until 2014, Dr. Dere worked at Amgen, where he was Senior Vice President and head of Global Development, and led development programs in multiple therapeutic areas. From 1989 to 2014, he worked at Eli Lilly and led multiple development programs, and also worked in clinical pharmacology, regulatory affairs and safety. Dr. Dere has served on the boards of directors of BioMarin Pharmaceutical, Inc. since 2016 and Metagenomi, Inc. since Augt 2021, and previoly served on the boards of directors of Mersana Therapeutics, Ocera Therapeutics and Radi Health. Dr. Dere received his B.A. in History and Zoology and M.D. from the University of California, Davis, completed his internal medicine residency training at the University of Utah, and his postdoctoral training in endocrinology and metabolism at the University of California, San Francisco.
- Eric D. Shaff
-
Eric D. Shaff，自2019年1月起担任总裁兼首席执行官、董事会成员。此前，他于2018年1月至2019年1月担任首席运营和财务官兼执行副总裁，于2014年11月至2019年1月担任首席财务官。2012年1月至2014年11月，Shaff先生担任生物技术公司摩蒙塔制药（Momenta）的企业财务副总裁，帮助管理Momenta的会计、财务、规划和采购职能，并为Momenta的投资者关系工作做出贡献。在加入Momenta之前，Shaff先生曾在生物技术公司健赞担任多个企业发展和财务职位，最近担任个性化遗传健康部门的财务副总裁/财务总监。Shaff先生自2017年11月起担任Sigilon Therapeutics，Inc.的董事会成员。沙夫先生获得了宾夕法尼亚大学的学士学位和康奈尔大学的工商管理硕士学位。
Eric D. Shaff has served as a member of board of directors since January 2019. Mr. Shaff has been the President and Chief Executive Officer of PsiThera, Inc. since September 2025. Previoly, he served as President and Chief Executive Officer beten January 2019 and July 2025 and as Chief Operating and Financial Officer and Executive Vice President beten January 2018 and January 2019 and as Chief Financial Officer beten November 2014 and January 2019. From January 2012 to November 2014, Mr. Shaff was Vice President of Corporate Finance for Momenta Pharmaceuticals, or Momenta, a biotechnology company, where he helped manage Momenta's accounting, finance, planning, and procurement functions, as ll as contributing to Momenta's investor relations efforts. Prior to Momenta, Mr. Shaff held a number of corporate development and finance positions with Genzyme Corporation, a biotechnology company, most recently as Vice President of Finance/Controller for the Personalized Genetic Health division. Mr. Shaff previoly served on the board of directors of Sigilon Therapeutics, Inc. from 2017 to Augt 2023. Mr. Shaff received his B.A. from the University of Pennsylvania and his M.B.A. from Cornell University. - Eric D. Shaff，自2019年1月起担任总裁兼首席执行官、董事会成员。此前，他于2018年1月至2019年1月担任首席运营和财务官兼执行副总裁，于2014年11月至2019年1月担任首席财务官。2012年1月至2014年11月，Shaff先生担任生物技术公司摩蒙塔制药（Momenta）的企业财务副总裁，帮助管理Momenta的会计、财务、规划和采购职能，并为Momenta的投资者关系工作做出贡献。在加入Momenta之前，Shaff先生曾在生物技术公司健赞担任多个企业发展和财务职位，最近担任个性化遗传健康部门的财务副总裁/财务总监。Shaff先生自2017年11月起担任Sigilon Therapeutics，Inc.的董事会成员。沙夫先生获得了宾夕法尼亚大学的学士学位和康奈尔大学的工商管理硕士学位。
- Eric D. Shaff has served as a member of board of directors since January 2019. Mr. Shaff has been the President and Chief Executive Officer of PsiThera, Inc. since September 2025. Previoly, he served as President and Chief Executive Officer beten January 2019 and July 2025 and as Chief Operating and Financial Officer and Executive Vice President beten January 2018 and January 2019 and as Chief Financial Officer beten November 2014 and January 2019. From January 2012 to November 2014, Mr. Shaff was Vice President of Corporate Finance for Momenta Pharmaceuticals, or Momenta, a biotechnology company, where he helped manage Momenta's accounting, finance, planning, and procurement functions, as ll as contributing to Momenta's investor relations efforts. Prior to Momenta, Mr. Shaff held a number of corporate development and finance positions with Genzyme Corporation, a biotechnology company, most recently as Vice President of Finance/Controller for the Personalized Genetic Health division. Mr. Shaff previoly served on the board of directors of Sigilon Therapeutics, Inc. from 2017 to Augt 2023. Mr. Shaff received his B.A. from the University of Pennsylvania and his M.B.A. from Cornell University.
- Richard N. Kender
-
Richard N. Kender，自2014年10月起担任董事会成员。从1978年10月到2013年9月，Kender先生曾在默克制药公司或默沙东一家制药公司的多个企业领域任职，最近担任业务发展和企业许可高级副总裁。Kender先生自2015年3月起担任Poxel S.A.的董事会成员，自2019年7月起担任Bicycle治疗 PLC的董事会成员，自2019年11月起担任ReViral Ltd的董事会成员。他此前曾于2014年12月至2017年8月期间担任INC Research Holdings，Inc.的董事会成员，并于2015年12月至2019年5月期间担任Abide Therapeutics，Inc.的董事会成员。Kender先生在维拉诺瓦大学获得会计学学士学位，在费尔利·迪金森大学获得工商管理硕士学位。
Richard N. Kender has served as Executive Chair and Interim Chief Executive Officer since March 2026 and has been a member of board of directors since October 2014. From October 1978 to September 2013, Mr. Kender held positions in a variety of corporate areas at Merck & Co., Inc., or Merck, a pharmaceutical company, most recently serving as Senior Vice President of Biness Development and Corporate Licensing. Mr. Kender has served on the board of directors of Longeveron Inc. since May 2024. He previoly served on the boards of directors of Poxel S.A. beten March 2015 and July 2025, Bicycle Therapeutics PLC beten July 2019 and June 2025, INC Research Holdings, Inc. (now known as Syneos Health) beten December 2014 and Augt 2017, Abide Therapeutics, Inc., a privately held company, beten December 2015 and May 2019, Omega Therapeutics beten June 2024 and April 2025, and ReViral Ltd., a privately held company, from November 2019 to June 2022. Mr. Kender received a B.S. in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University. - Richard N. Kender，自2014年10月起担任董事会成员。从1978年10月到2013年9月，Kender先生曾在默克制药公司或默沙东一家制药公司的多个企业领域任职，最近担任业务发展和企业许可高级副总裁。Kender先生自2015年3月起担任Poxel S.A.的董事会成员，自2019年7月起担任Bicycle治疗 PLC的董事会成员，自2019年11月起担任ReViral Ltd的董事会成员。他此前曾于2014年12月至2017年8月期间担任INC Research Holdings，Inc.的董事会成员，并于2015年12月至2019年5月期间担任Abide Therapeutics，Inc.的董事会成员。Kender先生在维拉诺瓦大学获得会计学学士学位，在费尔利·迪金森大学获得工商管理硕士学位。
- Richard N. Kender has served as Executive Chair and Interim Chief Executive Officer since March 2026 and has been a member of board of directors since October 2014. From October 1978 to September 2013, Mr. Kender held positions in a variety of corporate areas at Merck & Co., Inc., or Merck, a pharmaceutical company, most recently serving as Senior Vice President of Biness Development and Corporate Licensing. Mr. Kender has served on the board of directors of Longeveron Inc. since May 2024. He previoly served on the boards of directors of Poxel S.A. beten March 2015 and July 2025, Bicycle Therapeutics PLC beten July 2019 and June 2025, INC Research Holdings, Inc. (now known as Syneos Health) beten December 2014 and Augt 2017, Abide Therapeutics, Inc., a privately held company, beten December 2015 and May 2019, Omega Therapeutics beten June 2024 and April 2025, and ReViral Ltd., a privately held company, from November 2019 to June 2022. Mr. Kender received a B.S. in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University.
- Kurt C. Graves
-
Kurt C. Graves，自2015年11月起担任董事会成员。Graves先生曾于2012年4月至2020年12月担任Intarcia Therapeutics，Inc.或生物技术公司Intarcia的董事长、总裁兼首席执行官，并于2010年8月至2012年4月担任执行主席。Graves先生此前还曾在2010年11月至2012年3月期间担任生物制药公司Biolex Therapeutics的执行董事长。此前，他于2007年7月至2009年10月在福泰制药 Inc.（简称福泰制药）担任执行副总裁、首席商务官和战略发展主管。在加入福泰制药之前，Graves先生于1999年至2007年6月在诺华制药公司（Novartis Corp.）担任过多个领导职务，包括于2003年9月至2007年6月担任诺华公司制药部门的首席营销官。他于2011年5月至2020年3月在Radius Health，Inc.担任董事会董事，于2012年6月至2020年1月在爱克莱恩制药。格雷夫斯先生获得了希尔斯代尔学院的生物学学士学位。
Kurt C. Graves has served as a member of board of directors since November 2015. Mr. Graves has served as the Chairman, President and Chief Executive Officer of i20 Therapeutics, Inc., a biotechnology company, since Augt 2023, and as a director since Augt 2021. He previoly served as the Executive Chairman of i20 Therapeutics' board of directors from Augt 2021 to Augt 2023. Mr. Graves was previoly the Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc., a biotechnology company, from September 2010 to December 2020, and on its board of directors from Augt 2010 to December 2020. Previoly, he served as Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Vertex Pharmaceuticals Inc., or Vertex, from July 2007 to October 2009. Prior to joining Vertex, Mr. Graves held vario senior leadership positions at Novartis Pharmaceuticals Corporation, or Novartis Corp., from 1999 to June 2007, including the Global General Medicines Biness Unit Head and Global Chief Marketing Officer for the pharmaceuticals division of Novartis Corp. from September 2003 to June 2007. Prior to Novartis Corp., Mr. Graves held senior leadership positions at Merck and Astra Merck where he led the U.S. Biness Unit responsible for Prilosec, Nexium and Prilosec OTC over a 10 year period. He served as Chairman on the board of directors of Radi Health, Inc. from May 2011 to March 2020, and as a director on Achillion Pharmaceuticals, Inc., or Achillion, from June 2012 to January 2020, when Achillion was acquired. Mr. Graves received a B.S. in Biology from Hillsdale College. - Kurt C. Graves，自2015年11月起担任董事会成员。Graves先生曾于2012年4月至2020年12月担任Intarcia Therapeutics，Inc.或生物技术公司Intarcia的董事长、总裁兼首席执行官，并于2010年8月至2012年4月担任执行主席。Graves先生此前还曾在2010年11月至2012年3月期间担任生物制药公司Biolex Therapeutics的执行董事长。此前，他于2007年7月至2009年10月在福泰制药 Inc.（简称福泰制药）担任执行副总裁、首席商务官和战略发展主管。在加入福泰制药之前，Graves先生于1999年至2007年6月在诺华制药公司（Novartis Corp.）担任过多个领导职务，包括于2003年9月至2007年6月担任诺华公司制药部门的首席营销官。他于2011年5月至2020年3月在Radius Health，Inc.担任董事会董事，于2012年6月至2020年1月在爱克莱恩制药。格雷夫斯先生获得了希尔斯代尔学院的生物学学士学位。
- Kurt C. Graves has served as a member of board of directors since November 2015. Mr. Graves has served as the Chairman, President and Chief Executive Officer of i20 Therapeutics, Inc., a biotechnology company, since Augt 2023, and as a director since Augt 2021. He previoly served as the Executive Chairman of i20 Therapeutics' board of directors from Augt 2021 to Augt 2023. Mr. Graves was previoly the Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc., a biotechnology company, from September 2010 to December 2020, and on its board of directors from Augt 2010 to December 2020. Previoly, he served as Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Vertex Pharmaceuticals Inc., or Vertex, from July 2007 to October 2009. Prior to joining Vertex, Mr. Graves held vario senior leadership positions at Novartis Pharmaceuticals Corporation, or Novartis Corp., from 1999 to June 2007, including the Global General Medicines Biness Unit Head and Global Chief Marketing Officer for the pharmaceuticals division of Novartis Corp. from September 2003 to June 2007. Prior to Novartis Corp., Mr. Graves held senior leadership positions at Merck and Astra Merck where he led the U.S. Biness Unit responsible for Prilosec, Nexium and Prilosec OTC over a 10 year period. He served as Chairman on the board of directors of Radi Health, Inc. from May 2011 to March 2020, and as a director on Achillion Pharmaceuticals, Inc., or Achillion, from June 2012 to January 2020, when Achillion was acquired. Mr. Graves received a B.S. in Biology from Hillsdale College.
- Stephen Berenson
-
Stephen Berenson是旗舰创业公司的管理合伙人。在此之前，贝伦森在摩根大通做了33年的投资银行家。在摩根大通（J.P.Morgan）任职的最后12年里，贝伦森担任投资银行业务副主席，专注于为全球各行业的领先企业提供高接触度的战略建议和复杂的交易执行。他是摩根大通全球战略咨询委员会（J.P.Morgan'sGlobalStrategicAdvisoryCouncil）的联合创始人，也是该公司董事会计划（BoardInitiative）的联合创始人。他是CiBO Technologies，Inc.S.B。的董事会成员。麻省理工学院数学系。
Stephen Berenson has served as a member of board of directors since Augt 2019 and served as Chairman beten December 2019 and March 2026. Mr. Berenson is an Advisor Partner at Flagship Pioneering, a life sciences innovation firm which conceives, creates, resces and develops first in category bioplatform companies, after serving as Managing Partner since June 2017. Prior to Flagship, Mr. Berenson spent 33 years in vario roles as an investment banker at J.P. Morgan, most recently serving in the role of Vice Chairman of Investment Banking from 2005 to April 2017, where he foced on providing high touch strategic advice and complex transaction execution to leading companies across all indtries globally. He was co founder of J.P. Morgan's Global Strategic Advisory Council and co founder of the firm's Board Initiative. Mr. Berenson has served on the board of directors of Inari, a privately held agricultural company, since January 2024. He previoly served as chairman of the board of directors of Cellarity, a privately held pharmaceutical company beten July 2021and December 2025, as chairman of SAIL Biomedicines, a privately held pharmaceutical company, beten Augt 2024 and December 2025, and on the board of directors of Moderna, Inc., a pharmaceutical and biotechnology company, beten October 2017 and Augt 2024. Mr. Berenson received an S.B. in Mathematics from the Massachetts Institute of Technology. - Stephen Berenson是旗舰创业公司的管理合伙人。在此之前，贝伦森在摩根大通做了33年的投资银行家。在摩根大通（J.P.Morgan）任职的最后12年里，贝伦森担任投资银行业务副主席，专注于为全球各行业的领先企业提供高接触度的战略建议和复杂的交易执行。他是摩根大通全球战略咨询委员会（J.P.Morgan'sGlobalStrategicAdvisoryCouncil）的联合创始人，也是该公司董事会计划（BoardInitiative）的联合创始人。他是CiBO Technologies，Inc.S.B。的董事会成员。麻省理工学院数学系。
- Stephen Berenson has served as a member of board of directors since Augt 2019 and served as Chairman beten December 2019 and March 2026. Mr. Berenson is an Advisor Partner at Flagship Pioneering, a life sciences innovation firm which conceives, creates, resces and develops first in category bioplatform companies, after serving as Managing Partner since June 2017. Prior to Flagship, Mr. Berenson spent 33 years in vario roles as an investment banker at J.P. Morgan, most recently serving in the role of Vice Chairman of Investment Banking from 2005 to April 2017, where he foced on providing high touch strategic advice and complex transaction execution to leading companies across all indtries globally. He was co founder of J.P. Morgan's Global Strategic Advisory Council and co founder of the firm's Board Initiative. Mr. Berenson has served on the board of directors of Inari, a privately held agricultural company, since January 2024. He previoly served as chairman of the board of directors of Cellarity, a privately held pharmaceutical company beten July 2021and December 2025, as chairman of SAIL Biomedicines, a privately held pharmaceutical company, beten Augt 2024 and December 2025, and on the board of directors of Moderna, Inc., a pharmaceutical and biotechnology company, beten October 2017 and Augt 2024. Mr. Berenson received an S.B. in Mathematics from the Massachetts Institute of Technology.
- Robert Rosiello
-
Robert Rosiello，自2022年10月起担任Axcella Health公司董事会成员。Rosiello先生是Flagship Pioneering的执行合伙人，他于2018年加入该公司，专注于建立能力，帮助创立、管理和发展新的旗舰公司。他还与高级领导层合作，推动旗舰公司的战略、机构建设和增长计划。从1984年9月到2015年6月，罗西洛先生在麦肯锡公司工作，为领先的医疗保健、科技和消费公司的首席执行官和董事会提供咨询。他担任了18年的高级合伙人，并且是麦肯锡高级合伙人审查和薪酬委员会的成员。2015年7月至2016年8月，Rosiello先生在Valeant Pharmaceuticals担任执行副总裁兼首席财务官，负责财务、人力资源和IT职能。自2023年4月以来，他一直在Evelo Biosciences, Inc.（纳斯达克股票代码：EVLO）董事会任职。他目前在纽约天主教慈善组织董事会和执行委员会以及莫尔黑德-凯恩基金会中央甄选委员会任职。他曾在皮尤研究中心和稻岭农业的董事会任职。罗西洛在北卡罗来纳大学获得经济学学士学位，在那里他是一名莫尔黑德学者，毕业于伦敦政治经济学院经济学硕士学位Phi Beta Kappa和哈佛商学院工商管理硕士学位。
Robert Rosiello,has served as a member of Axcella Health Inc. board of directors since October 2022. Mr. Rosiello is an Executive Partner at Flagship Pioneering, which he joined in 2018 and where he focuses on building capability to help originate, manage, and grow new Flagship companies. He also works with senior leadership to drive Flagship's strategy, institution building, and growth initiatives. From September 1984 to June 2015, Mr. Rosiello worked at McKinsey & Company advising CEOs and boards of leading health care, technology, and consumer companies. He served as a senior partner for 18 years and was a member of McKinsey's Senior Partner Review and Compensation Committees. From July 2015 to August 2016, Mr. Rosiello was both Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals, where he led the finance, human resources, and IT functions. He has served on the Board Evelo Biosciences, Inc. (NASDAQ: EVLO) since April 2023. He currently serves on the Board and Executive Committee of Catholic Charities of New York and the Central Selection Committee of the Morehead-Cain Foundation. He previously served on the Boards of the Pew Research Center and Inari Agriculture. Mr. Rosiello received his B.A. in economics from the University of North Carolina, where he was a Morehead Scholar and graduated Phi Beta Kappa, an M.Sc. in economics from the London School of Economics, and an M.B.A. from Harvard Business School. - Robert Rosiello，自2022年10月起担任Axcella Health公司董事会成员。Rosiello先生是Flagship Pioneering的执行合伙人，他于2018年加入该公司，专注于建立能力，帮助创立、管理和发展新的旗舰公司。他还与高级领导层合作，推动旗舰公司的战略、机构建设和增长计划。从1984年9月到2015年6月，罗西洛先生在麦肯锡公司工作，为领先的医疗保健、科技和消费公司的首席执行官和董事会提供咨询。他担任了18年的高级合伙人，并且是麦肯锡高级合伙人审查和薪酬委员会的成员。2015年7月至2016年8月，Rosiello先生在Valeant Pharmaceuticals担任执行副总裁兼首席财务官，负责财务、人力资源和IT职能。自2023年4月以来，他一直在Evelo Biosciences, Inc.（纳斯达克股票代码：EVLO）董事会任职。他目前在纽约天主教慈善组织董事会和执行委员会以及莫尔黑德-凯恩基金会中央甄选委员会任职。他曾在皮尤研究中心和稻岭农业的董事会任职。罗西洛在北卡罗来纳大学获得经济学学士学位，在那里他是一名莫尔黑德学者，毕业于伦敦政治经济学院经济学硕士学位Phi Beta Kappa和哈佛商学院工商管理硕士学位。
- Robert Rosiello,has served as a member of Axcella Health Inc. board of directors since October 2022. Mr. Rosiello is an Executive Partner at Flagship Pioneering, which he joined in 2018 and where he focuses on building capability to help originate, manage, and grow new Flagship companies. He also works with senior leadership to drive Flagship's strategy, institution building, and growth initiatives. From September 1984 to June 2015, Mr. Rosiello worked at McKinsey & Company advising CEOs and boards of leading health care, technology, and consumer companies. He served as a senior partner for 18 years and was a member of McKinsey's Senior Partner Review and Compensation Committees. From July 2015 to August 2016, Mr. Rosiello was both Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals, where he led the finance, human resources, and IT functions. He has served on the Board Evelo Biosciences, Inc. (NASDAQ: EVLO) since April 2023. He currently serves on the Board and Executive Committee of Catholic Charities of New York and the Central Selection Committee of the Morehead-Cain Foundation. He previously served on the Boards of the Pew Research Center and Inari Agriculture. Mr. Rosiello received his B.A. in economics from the University of North Carolina, where he was a Morehead Scholar and graduated Phi Beta Kappa, an M.Sc. in economics from the London School of Economics, and an M.B.A. from Harvard Business School.
- Hans Juergen Woerle
-
Hans Juergen Woerle自2025年2月起担任董事会成员。Woerle博士自2018年11月起担任雀巢健康科学公司的首席医疗官和首席科学官，负责全球研发战略。Woerle博士于2020年6月至2024年9月担任临床阶段生物技术公司Cerecin Inc.的董事会成员，并于2020年6月至2025年3月担任临床阶段生物制药公司Enterome，SA的董事会成员。Woerle博士是一名董事会认证医师，也是内科和内分泌学专家，在乌尔姆大学担任兼职教授。Woerle博士在路德维希·马克西米利安大学获得学士学位、硕士学位和医学学位。
Hans Juergen Woerle has served as a member of board of directors since February 2025. Dr. Woerle has served as Chief Medical Officer and Chief Scientific Officer at Nestlé Health Science S.A. since November 2018, where he is responsible for global research and development strategy. Dr. Woerle served on the boards of directors of Cerecin Inc., a clinical stage biotechnology company, from June 2020 to September 2024 and Enterome, SA, a clinical stage biopharmaceutical company from June 2020 to March 2025. Dr. Woerle is a board certified physician and a specialist in internal medicine and endocrinology, holding an adjunct professorship at University of Ulm. Dr. Woerle earned his bachelor's degree, master's degree and medical degree from Ludwig Maximilian University. - Hans Juergen Woerle自2025年2月起担任董事会成员。Woerle博士自2018年11月起担任雀巢健康科学公司的首席医疗官和首席科学官，负责全球研发战略。Woerle博士于2020年6月至2024年9月担任临床阶段生物技术公司Cerecin Inc.的董事会成员，并于2020年6月至2025年3月担任临床阶段生物制药公司Enterome，SA的董事会成员。Woerle博士是一名董事会认证医师，也是内科和内分泌学专家，在乌尔姆大学担任兼职教授。Woerle博士在路德维希·马克西米利安大学获得学士学位、硕士学位和医学学位。
- Hans Juergen Woerle has served as a member of board of directors since February 2025. Dr. Woerle has served as Chief Medical Officer and Chief Scientific Officer at Nestlé Health Science S.A. since November 2018, where he is responsible for global research and development strategy. Dr. Woerle served on the boards of directors of Cerecin Inc., a clinical stage biotechnology company, from June 2020 to September 2024 and Enterome, SA, a clinical stage biopharmaceutical company from June 2020 to March 2025. Dr. Woerle is a board certified physician and a specialist in internal medicine and endocrinology, holding an adjunct professorship at University of Ulm. Dr. Woerle earned his bachelor's degree, master's degree and medical degree from Ludwig Maximilian University.
- Claire M. Fraser
-
Claire M. Fraser Liggett自2006年担任董事。自2007年她担任基因组科学协会董事，马里兰巴尔的摩的马里兰大学医学院教授。从1998年至2007年担任基因组研究协会的总裁和主管，该协会是非盈利的破译分析基因的中心。Dr. Fraser在美国科学院董事会工作。Dr. Fraser因其在传染病和分子诊断方面的著名科学家，脑阔新型诊断的发展和疫苗。
Claire M. Fraser Liggett is the Director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine since 2007. She served as President and Director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies, from 1998 to 2007.Chair of the Board and a Director of the American Association for the Advancement of Science.Previously served as a Director of Ohana Biosciences Inc. - Claire M. Fraser Liggett自2006年担任董事。自2007年她担任基因组科学协会董事，马里兰巴尔的摩的马里兰大学医学院教授。从1998年至2007年担任基因组研究协会的总裁和主管，该协会是非盈利的破译分析基因的中心。Dr. Fraser在美国科学院董事会工作。Dr. Fraser因其在传染病和分子诊断方面的著名科学家，脑阔新型诊断的发展和疫苗。
- Claire M. Fraser Liggett is the Director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine since 2007. She served as President and Director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies, from 1998 to 2007.Chair of the Board and a Director of the American Association for the Advancement of Science.Previously served as a Director of Ohana Biosciences Inc.
- Dennis A. Ausiello
-
Dennis A. Ausiello，自2015年4月起担任董事会成员。Ausiello博士自1996年起担任哈佛医学院杰克逊临床医学特聘教授和哈佛医学院医学博士/博士项目名誉主任，自2012年起担任医学、名誉主席，并担任他共同创立的麻省总医院评估技术和持续健康CACH中心主任，自2013年起担任麻省总医院名誉主任医师。从1996年到2013年4月，Ausiello博士担任麻省总医院的医学主任。Ausiello博士是美国国家科学院医学研究所的成员，也是美国艺术与科学院的研究员。Ausiello博士自2012年4月起担任阿尔尼拉姆制药董事会成员，此前曾于2006年至2019年担任辉瑞公司董事会成员，目前自2019年起担任顾问委员会成员。Ausiello博士还在多家私营公司的董事会任职。Ausiello博士获得了哈佛学院的生物化学学士学位和宾夕法尼亚大学的医学博士学位。
Dennis A. Ausiello has served as a member of board of directors since April 2015. Dr. Aiello has served as the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Director, Emerit of Harvard Medical School's M.D./Ph.D. Program since 1996, Chair of Medicine, Emerit, and Director of the Center for Assessment Technology and Continuo Health (CATCH) at Massachetts General Hospital, which he co founded, since 2012, and Physician in Chief Emerit at Massachetts General Hospital since 2013. From 1996 to April 2013, Dr. Aiello served as the Chief of Medicine at Massachetts General Hospital. Dr. Aiello is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Aiello has served on the board of directors of Alnylam Pharmaceuticals since April 2012, and previoly served as Vice Chairman of the board of directors of Spexis AG, a clinical stage biopharmaceutical company, from December 2021 to December 2025 and on the board of directors of Pfizer Inc. from 2006 to 2020, where he currently serves on the advisory board since 2019. Dr. Aiello also serves on the boards of directors of numero privately held companies. Dr. Aiello received a B.A. in Biochemistry from Harvard College and an M.D. from the University of Pennsylvania. - Dennis A. Ausiello，自2015年4月起担任董事会成员。Ausiello博士自1996年起担任哈佛医学院杰克逊临床医学特聘教授和哈佛医学院医学博士/博士项目名誉主任，自2012年起担任医学、名誉主席，并担任他共同创立的麻省总医院评估技术和持续健康CACH中心主任，自2013年起担任麻省总医院名誉主任医师。从1996年到2013年4月，Ausiello博士担任麻省总医院的医学主任。Ausiello博士是美国国家科学院医学研究所的成员，也是美国艺术与科学院的研究员。Ausiello博士自2012年4月起担任阿尔尼拉姆制药董事会成员，此前曾于2006年至2019年担任辉瑞公司董事会成员，目前自2019年起担任顾问委员会成员。Ausiello博士还在多家私营公司的董事会任职。Ausiello博士获得了哈佛学院的生物化学学士学位和宾夕法尼亚大学的医学博士学位。
- Dennis A. Ausiello has served as a member of board of directors since April 2015. Dr. Aiello has served as the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Director, Emerit of Harvard Medical School's M.D./Ph.D. Program since 1996, Chair of Medicine, Emerit, and Director of the Center for Assessment Technology and Continuo Health (CATCH) at Massachetts General Hospital, which he co founded, since 2012, and Physician in Chief Emerit at Massachetts General Hospital since 2013. From 1996 to April 2013, Dr. Aiello served as the Chief of Medicine at Massachetts General Hospital. Dr. Aiello is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Aiello has served on the board of directors of Alnylam Pharmaceuticals since April 2012, and previoly served as Vice Chairman of the board of directors of Spexis AG, a clinical stage biopharmaceutical company, from December 2021 to December 2025 and on the board of directors of Pfizer Inc. from 2006 to 2020, where he currently serves on the advisory board since 2019. Dr. Aiello also serves on the boards of directors of numero privately held companies. Dr. Aiello received a B.A. in Biochemistry from Harvard College and an M.D. from the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Richard N. Kender
Richard N. Kender，自2014年10月起担任董事会成员。从1978年10月到2013年9月，Kender先生曾在默克制药公司或默沙东一家制药公司的多个企业领域任职，最近担任业务发展和企业许可高级副总裁。Kender先生自2015年3月起担任Poxel S.A.的董事会成员，自2019年7月起担任Bicycle治疗 PLC的董事会成员，自2019年11月起担任ReViral Ltd的董事会成员。他此前曾于2014年12月至2017年8月期间担任INC Research Holdings，Inc.的董事会成员，并于2015年12月至2019年5月期间担任Abide Therapeutics，Inc.的董事会成员。Kender先生在维拉诺瓦大学获得会计学学士学位，在费尔利·迪金森大学获得工商管理硕士学位。
Richard N. Kender has served as Executive Chair and Interim Chief Executive Officer since March 2026 and has been a member of board of directors since October 2014. From October 1978 to September 2013, Mr. Kender held positions in a variety of corporate areas at Merck & Co., Inc., or Merck, a pharmaceutical company, most recently serving as Senior Vice President of Biness Development and Corporate Licensing. Mr. Kender has served on the board of directors of Longeveron Inc. since May 2024. He previoly served on the boards of directors of Poxel S.A. beten March 2015 and July 2025, Bicycle Therapeutics PLC beten July 2019 and June 2025, INC Research Holdings, Inc. (now known as Syneos Health) beten December 2014 and Augt 2017, Abide Therapeutics, Inc., a privately held company, beten December 2015 and May 2019, Omega Therapeutics beten June 2024 and April 2025, and ReViral Ltd., a privately held company, from November 2019 to June 2022. Mr. Kender received a B.S. in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University.- Richard N. Kender，自2014年10月起担任董事会成员。从1978年10月到2013年9月，Kender先生曾在默克制药公司或默沙东一家制药公司的多个企业领域任职，最近担任业务发展和企业许可高级副总裁。Kender先生自2015年3月起担任Poxel S.A.的董事会成员，自2019年7月起担任Bicycle治疗 PLC的董事会成员，自2019年11月起担任ReViral Ltd的董事会成员。他此前曾于2014年12月至2017年8月期间担任INC Research Holdings，Inc.的董事会成员，并于2015年12月至2019年5月期间担任Abide Therapeutics，Inc.的董事会成员。Kender先生在维拉诺瓦大学获得会计学学士学位，在费尔利·迪金森大学获得工商管理硕士学位。
- Richard N. Kender has served as Executive Chair and Interim Chief Executive Officer since March 2026 and has been a member of board of directors since October 2014. From October 1978 to September 2013, Mr. Kender held positions in a variety of corporate areas at Merck & Co., Inc., or Merck, a pharmaceutical company, most recently serving as Senior Vice President of Biness Development and Corporate Licensing. Mr. Kender has served on the board of directors of Longeveron Inc. since May 2024. He previoly served on the boards of directors of Poxel S.A. beten March 2015 and July 2025, Bicycle Therapeutics PLC beten July 2019 and June 2025, INC Research Holdings, Inc. (now known as Syneos Health) beten December 2014 and Augt 2017, Abide Therapeutics, Inc., a privately held company, beten December 2015 and May 2019, Omega Therapeutics beten June 2024 and April 2025, and ReViral Ltd., a privately held company, from November 2019 to June 2022. Mr. Kender received a B.S. in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University.
- Marella Thorell
Marella Thorell预计将担任我们的董事会成员，并在本次发行完成后担任我们的审计委员会主席。她是Palladio Biosciences公司的首席财务官。最近，Thorell女士担任Realm Therapeutics的首席财务官/首席运营官兼执行董事，该公司于2019年7月被ESSA Pharma收购，此前曾在Realm担任多个其他高级职位。Thorell女士在收购后被任命为ESSA的董事。Thorell女士曾在康宝浓汤公司工作，担任多个财务和管理职务，责任越来越大。她也曾担任执行顾问，专注于财务和人力资本项目。她的职业生涯始于任职Ernst&Young，LLP，并获得注册会计师资格。Thorell女士以优异成绩获得利哈伊大学（Lehigh University）商学学士学位。
Marella Thorell,has been a member of ESSA's board since 2019 and was Chief Financial Officer of Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects through December 2023. Ms. Thorell has more than 25 years of experience in finance and operations. Prior to Evelo, Ms. Thorell served as Chief Accounting Officer at Centessa Pharmaceuticals plc (Nasdaq: CNTA) where she led the establishment of Centessa's finance operations, its public company readiness activities in connection with its initial public offering and oversaw finance and accounting operations. Prior to that, she was the Chief Financial Officer of Palladio Biosciences Inc., before its acquisition by Centessa. Previously, Ms. Thorell served as Chief Financial Officer, Chief Operating Officer and Executive Director of Realm Therapeutics plc ("Realm") until the company was acquired by ESSA in 2019. At Realm, Ms. Thorell was responsible for in-licensing and out-licensing assets, and capital strategy to fund growth and clinical development. Ms. Thorell began her career and earned her CPA at Ernst & Young, LLP. Subsequently, she worked for Campbell Soup Company in finance and operational roles of increasing responsibility and served as an executive consultant focusing on financial and human capital projects. Ms. Thorell earned a B.S.in Business from Lehigh University, magna cum laude. Ms. Thorell served as a Director of Vallon Pharmaceuticals, including as Board Chair and Audit Committee Chair at different points during her tenure, from February 2021 until its merger with GRI Bio, Inc. in April 2023.- Marella Thorell预计将担任我们的董事会成员，并在本次发行完成后担任我们的审计委员会主席。她是Palladio Biosciences公司的首席财务官。最近，Thorell女士担任Realm Therapeutics的首席财务官/首席运营官兼执行董事，该公司于2019年7月被ESSA Pharma收购，此前曾在Realm担任多个其他高级职位。Thorell女士在收购后被任命为ESSA的董事。Thorell女士曾在康宝浓汤公司工作，担任多个财务和管理职务，责任越来越大。她也曾担任执行顾问，专注于财务和人力资本项目。她的职业生涯始于任职Ernst&Young，LLP，并获得注册会计师资格。Thorell女士以优异成绩获得利哈伊大学（Lehigh University）商学学士学位。
- Marella Thorell,has been a member of ESSA's board since 2019 and was Chief Financial Officer of Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects through December 2023. Ms. Thorell has more than 25 years of experience in finance and operations. Prior to Evelo, Ms. Thorell served as Chief Accounting Officer at Centessa Pharmaceuticals plc (Nasdaq: CNTA) where she led the establishment of Centessa's finance operations, its public company readiness activities in connection with its initial public offering and oversaw finance and accounting operations. Prior to that, she was the Chief Financial Officer of Palladio Biosciences Inc., before its acquisition by Centessa. Previously, Ms. Thorell served as Chief Financial Officer, Chief Operating Officer and Executive Director of Realm Therapeutics plc ("Realm") until the company was acquired by ESSA in 2019. At Realm, Ms. Thorell was responsible for in-licensing and out-licensing assets, and capital strategy to fund growth and clinical development. Ms. Thorell began her career and earned her CPA at Ernst & Young, LLP. Subsequently, she worked for Campbell Soup Company in finance and operational roles of increasing responsibility and served as an executive consultant focusing on financial and human capital projects. Ms. Thorell earned a B.S.in Business from Lehigh University, magna cum laude. Ms. Thorell served as a Director of Vallon Pharmaceuticals, including as Board Chair and Audit Committee Chair at different points during her tenure, from February 2021 until its merger with GRI Bio, Inc. in April 2023.
- Matthew Henn
Matthew Henn自2019年2月起担任我们的执行Vice President兼首席科学官。自2012年6月加入我们公司以来，他一直担任高级职位，最近的职位是2018年1月至2019年2月担任执行Vice President、发现和微生物组研发主管，此前曾担任高级副总裁，2012年6月至2018年1月担任发现和生物信息学主管。加入我公司之前，他是麻省理工学院布罗德研究所（Broad Institute of MIT）和哈佛大学（Harvard）病毒基因组学主任和传染病基因组测序中心助理主任。他目前任职于the Forsyth Institute、Growcentia，Inc.（农业微生物组公司）的科学顾问委员会。Henn博士在新罕布什尔大学（University of New Hampshire）获得生态学和进化科学学士学位，并在加州大学伯克利分校（University of California at Berkeley）获得生态系统科学博士学位，在那里他是NASA地球系统科学研究员，并在杜克大学（Duke University）接受微生物学NSF博士后培训。
Matthew Henn has served as President and Chief Scientific Officer since March 2026. He has also served as Executive Vice President and Chief Scientific Officer from February 2019 to March 2026. Dr. Henn has been involved in the discovery and development of multiple live biotherapeutics, including two breakthrough therapy designated biologics, across infectio, inflammatory, and oncology indications, and has authored over 75 peer revied publications. He has extensive research experience in microbiology, genomics, and computational biology, as ll as in drug pharmacology and clinical translation. His research has foced on microbial populations and the functional role of microbes in both environmental and human disease applications, and the development of genomic and functional screening technologies to study these populations. Prior to joining Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectio Diseases at the Broad Institute of Massachetts Institute of Technology and Harvard. He has served on vario National Institutes of Health, or NIH, working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH's Viral Pathogen Bioinformatics Resce Center, as an ad hoc revier and editor of vario peer revied jnals, and as a scientific advisor to non profit and for profit organizations. He currently serves on the Microbiome Therapeutics Innovation Group board of directors, the World Microbiome Partnership steering committee, and Life Sciences Cares board of advisors. Dr. Henn is formally trained in ecology and evolutionary biology and earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a National Science Foundation Postdoctoral Fellow in Microbiology at Duke University.- Matthew Henn自2019年2月起担任我们的执行Vice President兼首席科学官。自2012年6月加入我们公司以来，他一直担任高级职位，最近的职位是2018年1月至2019年2月担任执行Vice President、发现和微生物组研发主管，此前曾担任高级副总裁，2012年6月至2018年1月担任发现和生物信息学主管。加入我公司之前，他是麻省理工学院布罗德研究所（Broad Institute of MIT）和哈佛大学（Harvard）病毒基因组学主任和传染病基因组测序中心助理主任。他目前任职于the Forsyth Institute、Growcentia，Inc.（农业微生物组公司）的科学顾问委员会。Henn博士在新罕布什尔大学（University of New Hampshire）获得生态学和进化科学学士学位，并在加州大学伯克利分校（University of California at Berkeley）获得生态系统科学博士学位，在那里他是NASA地球系统科学研究员，并在杜克大学（Duke University）接受微生物学NSF博士后培训。
- Matthew Henn has served as President and Chief Scientific Officer since March 2026. He has also served as Executive Vice President and Chief Scientific Officer from February 2019 to March 2026. Dr. Henn has been involved in the discovery and development of multiple live biotherapeutics, including two breakthrough therapy designated biologics, across infectio, inflammatory, and oncology indications, and has authored over 75 peer revied publications. He has extensive research experience in microbiology, genomics, and computational biology, as ll as in drug pharmacology and clinical translation. His research has foced on microbial populations and the functional role of microbes in both environmental and human disease applications, and the development of genomic and functional screening technologies to study these populations. Prior to joining Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectio Diseases at the Broad Institute of Massachetts Institute of Technology and Harvard. He has served on vario National Institutes of Health, or NIH, working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH's Viral Pathogen Bioinformatics Resce Center, as an ad hoc revier and editor of vario peer revied jnals, and as a scientific advisor to non profit and for profit organizations. He currently serves on the Microbiome Therapeutics Innovation Group board of directors, the World Microbiome Partnership steering committee, and Life Sciences Cares board of advisors. Dr. Henn is formally trained in ecology and evolutionary biology and earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a National Science Foundation Postdoctoral Fellow in Microbiology at Duke University.
- Teresa L. Young
Teresa L.Young自2020年6月起担任我们的执行副总裁，首席商业和战略官。在此之前，Young博士于2018年3月至2020年6月担任Sage Therapeutics全球商业战略副总裁，她领导了Sage全球商业能力的开发，包括全球营销，见解和分析以及新产品规划。在此之前，她于2010年11月至2018年3月在Bristol-Myers Squibb担任越来越重要的商业领导职务，最终担任心血管副总裁兼总经理，领导全球Eliquis®；业务，成为公司收入最大的产品。在她的职业生涯早期，1993年6月至2010年11月，她在GlaxoSmithKline担任市场营销与销售，在那里她促进了公司泌尿科、糖尿病和神经健康组织的发展。Young博士是Women in Bio和医疗保健BusinessWomen’s Association的成员，并担任医疗保健BusinessWomen’s Association的顾问委员会成员。Young博士在南卡罗来纳大学获得药学学士学位和医疗保健营销博士学位。
Teresa L. Young has served as Executive Vice President, Chief Commercial and Strategy Officer since June 2020. Previoly, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics from March 2018 to June 2020, where she led development of Sage's global commercial capabilities, including global marketing, insights and analytics and new product planning. Prior to that, she held commercial leadership roles of increasing responsibility at Bristol Myers Squibb from November 2010 to March 2018, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS biness to become the company's largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline from June 1993 to November 2010, where she catalyzed growth for the company's Urology, Diabetes and NeuroHealth organizations. Dr. Young is a member of the Women in Bio and Healthcare Binesswomen's Association and served on the Advisory Board of the Healthcare Binesswomen's Association. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina.- Teresa L.Young自2020年6月起担任我们的执行副总裁，首席商业和战略官。在此之前，Young博士于2018年3月至2020年6月担任Sage Therapeutics全球商业战略副总裁，她领导了Sage全球商业能力的开发，包括全球营销，见解和分析以及新产品规划。在此之前，她于2010年11月至2018年3月在Bristol-Myers Squibb担任越来越重要的商业领导职务，最终担任心血管副总裁兼总经理，领导全球Eliquis®；业务，成为公司收入最大的产品。在她的职业生涯早期，1993年6月至2010年11月，她在GlaxoSmithKline担任市场营销与销售，在那里她促进了公司泌尿科、糖尿病和神经健康组织的发展。Young博士是Women in Bio和医疗保健BusinessWomen’s Association的成员，并担任医疗保健BusinessWomen’s Association的顾问委员会成员。Young博士在南卡罗来纳大学获得药学学士学位和医疗保健营销博士学位。
- Teresa L. Young has served as Executive Vice President, Chief Commercial and Strategy Officer since June 2020. Previoly, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics from March 2018 to June 2020, where she led development of Sage's global commercial capabilities, including global marketing, insights and analytics and new product planning. Prior to that, she held commercial leadership roles of increasing responsibility at Bristol Myers Squibb from November 2010 to March 2018, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS biness to become the company's largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline from June 1993 to November 2010, where she catalyzed growth for the company's Urology, Diabetes and NeuroHealth organizations. Dr. Young is a member of the Women in Bio and Healthcare Binesswomen's Association and served on the Advisory Board of the Healthcare Binesswomen's Association. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina.
- Marella Thorell
Marella Thorell自2024年3月起担任执行副总裁兼首席财务官。她还曾在2025年8月至2026年3月期间担任联席总裁/首席执行官。2022年9月至2023年12月，Thorell女士在生物技术公司Evelo Biosciences, Inc.担任首席财务官和财务主管。2021年1月至2022年7月，她在制药公司Centessa Pharmaceuticals PLC，即TERM1，担任首席会计官，并担任财务主管。在担任该职务期间，她领导了Centessa的财务运作的建立，领导了与首次公开发行股票相关的上市公司准备活动，并监督会计运作。Previoly，自2019年10月至2020年12月，Thorell女士在生物技术公司Palladio Biosciences担任首席财务官，此前该公司被Centessa收购。在此之前，Thorell女士曾在生物制药公司Realm Therapeutics PLC工作了十多年，担任过各种职责越来越重的角色，包括首席财务官和首席运营官。Thorell女士于2024年6月至2025年12月期间担任生物制药公司Carisma Therapeutics的董事会成员和审计委员会主席；Previoly于2019年7月至2025年10月期间担任制药公司ESSA Pharma Inc.的董事会成员，以及于2021年2月至2023年4月期间担任制药公司Vallon Pharmaceuticals, Inc.的董事会成员。Thorell女士拥有利哈伊大学的Biness学士学位。
Marella Thorell has served as Executive Vice President and Chief Financial Officer since March 2024. She has also served as Co President/Chief Executive Officer from Augt 2025 to March 2026. From September 2022 to December 2023, Ms. Thorell served as the Chief Financial Officer and Treasurer of Evelo Biosciences, Inc., a biotechnology company. From January 2021 to July 2022, she served as Chief Accounting Officer and previoly as Head of Finance at Centessa Pharmaceuticals PLC, or Centessa, a pharmaceutical company. In that role, she led the establishment of Centessa's finance operations, led its public company readiness activities in connection with its initial public offering, and oversaw accounting operations. Previoly, from October 2019 to December 2020, Ms. Thorell served as Chief Financial Officer at Palladio Biosciences, a biotechnology company, prior to its acquisition by Centessa. Before that, Ms. Thorell spent over ten years at Realm Therapeutics PLC, a biopharmaceutical company, serving in vario roles of increasing responsibility, including Chief Financial Officer and Chief Operating Officer. Ms. Thorell served on the board of directors and as the Audit Committee Chair of Carisma Therapeutics, a biopharmaceutical company, from June 2024 through December 2025 and previoly served on the boards of directors of ESSA Pharma Inc., a pharmaceutical company from July 2019 to October 2025, and Vallon Pharmaceuticals, Inc., a pharmaceutical company, from February 2021 until its reverse merger with GRI Bio in April 2023. Ms. Thorell holds a B.S. in Biness from Lehigh University.- Marella Thorell自2024年3月起担任执行副总裁兼首席财务官。她还曾在2025年8月至2026年3月期间担任联席总裁/首席执行官。2022年9月至2023年12月，Thorell女士在生物技术公司Evelo Biosciences, Inc.担任首席财务官和财务主管。2021年1月至2022年7月，她在制药公司Centessa Pharmaceuticals PLC，即TERM1，担任首席会计官，并担任财务主管。在担任该职务期间，她领导了Centessa的财务运作的建立，领导了与首次公开发行股票相关的上市公司准备活动，并监督会计运作。Previoly，自2019年10月至2020年12月，Thorell女士在生物技术公司Palladio Biosciences担任首席财务官，此前该公司被Centessa收购。在此之前，Thorell女士曾在生物制药公司Realm Therapeutics PLC工作了十多年，担任过各种职责越来越重的角色，包括首席财务官和首席运营官。Thorell女士于2024年6月至2025年12月期间担任生物制药公司Carisma Therapeutics的董事会成员和审计委员会主席；Previoly于2019年7月至2025年10月期间担任制药公司ESSA Pharma Inc.的董事会成员，以及于2021年2月至2023年4月期间担任制药公司Vallon Pharmaceuticals, Inc.的董事会成员。Thorell女士拥有利哈伊大学的Biness学士学位。
- Marella Thorell has served as Executive Vice President and Chief Financial Officer since March 2024. She has also served as Co President/Chief Executive Officer from Augt 2025 to March 2026. From September 2022 to December 2023, Ms. Thorell served as the Chief Financial Officer and Treasurer of Evelo Biosciences, Inc., a biotechnology company. From January 2021 to July 2022, she served as Chief Accounting Officer and previoly as Head of Finance at Centessa Pharmaceuticals PLC, or Centessa, a pharmaceutical company. In that role, she led the establishment of Centessa's finance operations, led its public company readiness activities in connection with its initial public offering, and oversaw accounting operations. Previoly, from October 2019 to December 2020, Ms. Thorell served as Chief Financial Officer at Palladio Biosciences, a biotechnology company, prior to its acquisition by Centessa. Before that, Ms. Thorell spent over ten years at Realm Therapeutics PLC, a biopharmaceutical company, serving in vario roles of increasing responsibility, including Chief Financial Officer and Chief Operating Officer. Ms. Thorell served on the board of directors and as the Audit Committee Chair of Carisma Therapeutics, a biopharmaceutical company, from June 2024 through December 2025 and previoly served on the boards of directors of ESSA Pharma Inc., a pharmaceutical company from July 2019 to October 2025, and Vallon Pharmaceuticals, Inc., a pharmaceutical company, from February 2021 until its reverse merger with GRI Bio in April 2023. Ms. Thorell holds a B.S. in Biness from Lehigh University.
- Kelly Brady
Kelly Brady自2026年3月起担任执行副总裁、首席运营官。她于2023年1月至2026年3月担任临床开发高级副总裁，在此之前，曾于2018年6月和2023年1月分别担任临床运营副总裁、临床运营执行总监和临床运营高级总监。在2018年加入公司之前，Brady女士是Akebia Therapeutics, Inc.的高级董事兼全球临床项目负责人，在那里她负责监督慢性肾病引起的贫血方面的关键项目。随着该公司最终被新基医药公司收购，她还在Acetylon Pharmaceuticals，Inc.的运营和项目管理方面担任了越来越多的职责。在她职业生涯的早期，她曾担任Millennium Pharmaceuticals，Inc.（后来的Takeda Oncology）的全球3期临床运营负责人，为ADCETRIS执行关键的全球肿瘤学试验，并且作为Osiris Therapeutics, Inc.运营团队的一员，为世界上第一个获批的干细胞疗法Prochymal管理全球移植物抗宿主疾病研究。Brady女士拥有拉斐特学院的神经科学学士学位和约翰霍普金斯大学的生物技术硕士学位。
Kelly Brady has served as Executive Vice President, Chief Operating Officer since March 2026. She served as Senior Vice President, Clinical Development from January 2023 to March 2026, and, prior to this, served as Vice President, Clinical Operations, Executive Director, Clinical Operations, and Senior Director, Clinical Operations beten June 2018 and January 2023. Prior to joining the Company in 2018, Ms. Brady was Senior Director and Global Clinical Program Lead at Akebia Therapeutics, Inc., where she oversaw pivotal programs in anemia due to chronic kidney disease. She also held roles of increasing responsibility in operations and program management at Acetylon Pharmaceuticals, Inc., with the company's eventual acquisition by Celgene Corporation. Earlier in her career, she served as the Global Phase 3 Clinical Operations Leader at Millennium Pharmaceuticals, Inc. (later Takeda Oncology), executing pivotal global oncology trials for ADCETRIS, and as a member of the operations team at Osiris Therapeutics, Inc., managing global graftvershost disease studies for the world's first approved stemcell therapy Prochymal. Ms. Brady holds a B.S. in Neuroscience from Lafayette College and an M.S. in Biotechnology from Johns Hopkins University.- Kelly Brady自2026年3月起担任执行副总裁、首席运营官。她于2023年1月至2026年3月担任临床开发高级副总裁，在此之前，曾于2018年6月和2023年1月分别担任临床运营副总裁、临床运营执行总监和临床运营高级总监。在2018年加入公司之前，Brady女士是Akebia Therapeutics, Inc.的高级董事兼全球临床项目负责人，在那里她负责监督慢性肾病引起的贫血方面的关键项目。随着该公司最终被新基医药公司收购，她还在Acetylon Pharmaceuticals，Inc.的运营和项目管理方面担任了越来越多的职责。在她职业生涯的早期，她曾担任Millennium Pharmaceuticals，Inc.（后来的Takeda Oncology）的全球3期临床运营负责人，为ADCETRIS执行关键的全球肿瘤学试验，并且作为Osiris Therapeutics, Inc.运营团队的一员，为世界上第一个获批的干细胞疗法Prochymal管理全球移植物抗宿主疾病研究。Brady女士拥有拉斐特学院的神经科学学士学位和约翰霍普金斯大学的生物技术硕士学位。
- Kelly Brady has served as Executive Vice President, Chief Operating Officer since March 2026. She served as Senior Vice President, Clinical Development from January 2023 to March 2026, and, prior to this, served as Vice President, Clinical Operations, Executive Director, Clinical Operations, and Senior Director, Clinical Operations beten June 2018 and January 2023. Prior to joining the Company in 2018, Ms. Brady was Senior Director and Global Clinical Program Lead at Akebia Therapeutics, Inc., where she oversaw pivotal programs in anemia due to chronic kidney disease. She also held roles of increasing responsibility in operations and program management at Acetylon Pharmaceuticals, Inc., with the company's eventual acquisition by Celgene Corporation. Earlier in her career, she served as the Global Phase 3 Clinical Operations Leader at Millennium Pharmaceuticals, Inc. (later Takeda Oncology), executing pivotal global oncology trials for ADCETRIS, and as a member of the operations team at Osiris Therapeutics, Inc., managing global graftvershost disease studies for the world's first approved stemcell therapy Prochymal. Ms. Brady holds a B.S. in Neuroscience from Lafayette College and an M.S. in Biotechnology from Johns Hopkins University.
- Thomas J. DesRosier
Thomas J. DesRosier自2016年5月起担任首席法务官、执行副总裁兼秘书。此前，他曾担任ARIAD Pharmaceuticals， Inc.（生物制药公司）的执行副总裁、首席法律和行政官兼秘书（2015年至2016年）；Cubist Pharmaceuticals, Inc.（生物制药公司Cubist）的执行副总裁、首席法律和行政官兼秘书（2014年至2015年）；Cubist的高级副总裁、首席法律官兼秘书（2013年至2014年）。在此之前，2011年至2013年，DesRosier先生担任Sanofi S.A.（全球生物制药公司）北美高级副总裁兼总法律顾问。从1999年到2011年，DesRosier先生在Genzyme Corporation（一家生物技术公司）的法务部担任领导职务，担任高级副总裁兼首席法务官。DesRosier先生自2017年6月起担任Avanir Pharmaceuticals （Otsuka Pharmaceutical Company, Ltd.的全资子公司）的董事会成员。他持有Vermont大学的化学学士学位和Wake Forest大学School of Law的法学博士学位。
Thomas J. DesRosier has served as Chief Legal Officer, Executive Vice President, and Secretary since May 2016. He has also served as Co President/Chief Executive Officer from July 2025 to March 2026. From 2015 to 2016, Mr. DesRosier served as Executive Vice President, Chief Legal and Administrative Officer and Secretary of ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, from 2014 to 2015 as Executive Vice President, Chief Legal and Administrative Officer and Secretary of Cubist Pharmaceuticals, Inc., or Cubist, a biopharmaceutical company, and from 2013 to 2014 as Senior Vice President, Chief Legal Officer and Secretary of Cubist. Before that, Mr. DesRosier served as Senior Vice President, General Counsel North America of Sanofi from 2011 to 2013. From 1999 to 2011, Mr. DesRosier held leadership roles of increasing seniority within the legal group of Genzyme Corporation, a biotechnology company, culminating in his role as Senior Vice President, Chief Legal Officer. Mr. DesRosier has served as a member of the board of directors of Avanir Pharmaceuticals, a privately held company and wholly owned subsidiary of Otsuka Pharmaceutical Company, Ltd., since June 2017. Mr. DesRosier earned a B.A. in Chemistry from the University of Vermont and a J.D. from Wake Forest University School of Law.- Thomas J. DesRosier自2016年5月起担任首席法务官、执行副总裁兼秘书。此前，他曾担任ARIAD Pharmaceuticals， Inc.（生物制药公司）的执行副总裁、首席法律和行政官兼秘书（2015年至2016年）；Cubist Pharmaceuticals, Inc.（生物制药公司Cubist）的执行副总裁、首席法律和行政官兼秘书（2014年至2015年）；Cubist的高级副总裁、首席法律官兼秘书（2013年至2014年）。在此之前，2011年至2013年，DesRosier先生担任Sanofi S.A.（全球生物制药公司）北美高级副总裁兼总法律顾问。从1999年到2011年，DesRosier先生在Genzyme Corporation（一家生物技术公司）的法务部担任领导职务，担任高级副总裁兼首席法务官。DesRosier先生自2017年6月起担任Avanir Pharmaceuticals （Otsuka Pharmaceutical Company, Ltd.的全资子公司）的董事会成员。他持有Vermont大学的化学学士学位和Wake Forest大学School of Law的法学博士学位。
- Thomas J. DesRosier has served as Chief Legal Officer, Executive Vice President, and Secretary since May 2016. He has also served as Co President/Chief Executive Officer from July 2025 to March 2026. From 2015 to 2016, Mr. DesRosier served as Executive Vice President, Chief Legal and Administrative Officer and Secretary of ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, from 2014 to 2015 as Executive Vice President, Chief Legal and Administrative Officer and Secretary of Cubist Pharmaceuticals, Inc., or Cubist, a biopharmaceutical company, and from 2013 to 2014 as Senior Vice President, Chief Legal Officer and Secretary of Cubist. Before that, Mr. DesRosier served as Senior Vice President, General Counsel North America of Sanofi from 2011 to 2013. From 1999 to 2011, Mr. DesRosier held leadership roles of increasing seniority within the legal group of Genzyme Corporation, a biotechnology company, culminating in his role as Senior Vice President, Chief Legal Officer. Mr. DesRosier has served as a member of the board of directors of Avanir Pharmaceuticals, a privately held company and wholly owned subsidiary of Otsuka Pharmaceutical Company, Ltd., since June 2017. Mr. DesRosier earned a B.A. in Chemistry from the University of Vermont and a J.D. from Wake Forest University School of Law.